Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 38kWORD 18k
12 July 2019
E-002267-19
Question for written answer E-002267-19
to the Commission
Rule 130
Roberta Metsola (PPE)

 Subject:  Fibromyalgia
 Answer in writing 

Fibromyalgia is a disorder characterised by chronic pain, with symptoms including muscular pains and aches in the ligaments and tendons. Symptoms can leave sufferers permanently exhausted and in pain, facing headaches, anxiety, cognitive dysfunction and non-restorative sleep, among other things, severely limiting their ability to work and their quality of life.

In terms of treating fibromyalgia and providing a long-term solution for sufferers from this disease, have there been any tangible outcomes so far from the Innovative Medicines Initiative?

Is the Commission planning on furthering this public-private partnership beyond 2020, and will fibromyalgia be a targeted priority area?

Last updated: 26 July 2019Legal notice